A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00477425

Enrollment

Registered

2007-05-23

Start date

2007-06-30

Completion date

2007-06-30

Last updated

2017-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma

Keywords

Avastin

Brief summary

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Signed Informed Consent Form * Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion criteria

* Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD) * Congenital long QT syndrome * Family history of long QT syndrome * Clinically significant bradycardia (defined as \< 50 beats/minute)

Outcome results